drugset / Trial / NCT04591262
A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants
NaSingle-groupOpen-labelOther
Summary
The purpose of the study is to determine the metabolism and excretion following a single oral administration of 14C-PF-06826647-LR (14C labelled PF-06826647 with lower radioactivity per mass unit) in fed conditions. This information will enable assessment of clearance mechanisms of PF-06826647 as well as identify metabolites. In addition, this study will determine absolute bioavailability of PF-06826647 and understand intravenous (IV) pharmacokinetic (PK).
Timeline
- Start
- 2020-11-10
- Primary completion
- 2021-01-28
- Completion
- 2021-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROPSACITINIB | Small molecule | 100 ug | Oral |
| Subject | ROPSACITINIB | Small molecule | 600 mg | Oral |
Indications
No indication recorded.